Association of Recurrences With Healthcare Resource Utilization in High-Risk Non-Muscle Invasive Bladder Cancer Patients Across Europe: A Real-World Survey
Author(s)
Siobhán Mulhern-Haughey, PhD1, Farah Hodeib, PharmD2, Marta Pisini, MBA, MSc3, Mia Unsworth, BSc4, Liane Gillespie-Akar, MSc4, Laure Manuel, MRes4, Jacob Skilling, BSc4, Emilia Biondi, MSci4, Elliott Brown, MRes4, Caitlin Ford, BSc4, Astrid Rijken-Knol, MD5, Neil Milloy, BA Hons4.
1Johnson and Johnson, Dublin, Ireland, 2Johnson & Johnson, Issy-les-Moulineaux, France, 3Johnson and Johnson, Beerse, Belgium, 4Adelphi Real World, Bollington, United Kingdom, 5Johnson and Johnson, Breda, Netherlands.
1Johnson and Johnson, Dublin, Ireland, 2Johnson & Johnson, Issy-les-Moulineaux, France, 3Johnson and Johnson, Beerse, Belgium, 4Adelphi Real World, Bollington, United Kingdom, 5Johnson and Johnson, Breda, Netherlands.
OBJECTIVES: To understand the association of recurrences with health care resource utilisation (HCRU) in patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC). Recurrences are defined as any high-grade Ta, any T1 or carcinoma in-situ tumour found in the bladder after treatment for HR-NMIBC.
METHODS: Data were drawn from the Adelphi Real World HR-NMIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of physicians and their consulting patients initially diagnosed with HR-NMIBC (high-grade Ta, T1 or carcinoma in situ tumours) in France, Germany, Spain, Italy and the United Kingdom from December 2023 to May 2024. Physicians reported HCRU for the next eight patients with HR-NMIBC who consulted consecutively. Negative binomial regression analysis was used to determine the association between number of recurrences and HCRU. Regressions were adjusted for age, sex and active treatment status. Incident rate ratios (IRRs) were reported for each covariate.
RESULTS: Overall, 244 physicians reported on 1648 patients, mean (SD) age was 70.0 (8.62) years and 73% were male. Where number of hospitalisations was known (n=1378), 15% had one or more within 12 months prior to data collection. At diagnosis, the most reported procedures were flexible cystoscopy (81%) and transurethral resection of bladder tumours (TURBT; 59%). Increased number of recurrences were significantly associated with an increased number of hospitalisations (IRR = 2.32, p<0.001). Also, an increased number of recurrences was significantly associated with increased number of procedures in the 12 months prior to data collection (IRR = 1.20, p=0.001) including increased number of flexible cystoscopy procedures (IRR = 1.11, p=0.007) and TURBTs (IRR = 1.35, p<0.001).
CONCLUSIONS: The number of recurrences was significantly associated with a higher number of procedures and hospitalisations in the 12 months prior to data collection, highlighting a need for novel treatments to reduce both recurrences and HCRU burden on patients with HR-NMIBC and health-care systems.
METHODS: Data were drawn from the Adelphi Real World HR-NMIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of physicians and their consulting patients initially diagnosed with HR-NMIBC (high-grade Ta, T1 or carcinoma in situ tumours) in France, Germany, Spain, Italy and the United Kingdom from December 2023 to May 2024. Physicians reported HCRU for the next eight patients with HR-NMIBC who consulted consecutively. Negative binomial regression analysis was used to determine the association between number of recurrences and HCRU. Regressions were adjusted for age, sex and active treatment status. Incident rate ratios (IRRs) were reported for each covariate.
RESULTS: Overall, 244 physicians reported on 1648 patients, mean (SD) age was 70.0 (8.62) years and 73% were male. Where number of hospitalisations was known (n=1378), 15% had one or more within 12 months prior to data collection. At diagnosis, the most reported procedures were flexible cystoscopy (81%) and transurethral resection of bladder tumours (TURBT; 59%). Increased number of recurrences were significantly associated with an increased number of hospitalisations (IRR = 2.32, p<0.001). Also, an increased number of recurrences was significantly associated with increased number of procedures in the 12 months prior to data collection (IRR = 1.20, p=0.001) including increased number of flexible cystoscopy procedures (IRR = 1.11, p=0.007) and TURBTs (IRR = 1.35, p<0.001).
CONCLUSIONS: The number of recurrences was significantly associated with a higher number of procedures and hospitalisations in the 12 months prior to data collection, highlighting a need for novel treatments to reduce both recurrences and HCRU burden on patients with HR-NMIBC and health-care systems.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD24
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology